Cargando…

Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk score

AIM: To assess the prognostic value of multiple recurrences on the risk of progression in a large cohort of TaG1 bladder cancer of low and intermediate risk based on the EORTC score and to evaluate prognostic factors of multiple recurrences. MATERIALS AND METHODS: We retrospectively analyzed a Frenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon, Marie, Bosset, Pierre-Olivier, Rouanne, Mathieu, Benhamou, Simone, Radulescu, Camelia, Molinié, Vincent, Neuzillet, Yann, Paoletti, Xavier, Lebret, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392242/ https://www.ncbi.nlm.nih.gov/pubmed/30811419 http://dx.doi.org/10.1371/journal.pone.0211721

Ejemplares similares

Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy
por: Neuzillet, Yann, et al.
Publicado: (2021)

Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy
por: Neuzillet, Yann, et al.
Publicado: (2021)

Value of positron emission tomography in diagnosing synchronous penile metastasis from urothelial bladder cancer
por: Rouanne, M., et al.
Publicado: (2015)

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers
por: Lebret, Thierry, et al.
Publicado: (2015)

Effects of Adenosine Monophosphate Used in Combination with L-Arginine on Female Rabbit Corpus Cavernosum Tissue
por: Stücker, Olivier, et al.
Publicado: (2014)

Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer
por: Rouanne, Mathieu, et al.
Publicado: (2020)

Author Correction: Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer
por: Rouanne, Mathieu, et al.
Publicado: (2021)

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)
por: Baumert, Brigitta G., et al.
Publicado: (2016)

A review of new hormonal therapies for prostate cancer in black men: is there enough data?
por: Meunier, Matthias E., et al.
Publicado: (2021)

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria
por: Lanese, Andrea, et al.
Publicado: (2018)

Expanding TAVI to Low and Intermediate Risk Patients
por: Voigtländer, Lisa, et al.
Publicado: (2018)

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033
por: Klein, Martin, et al.
Publicado: (2020)

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)
por: Fosså, S D, et al.
Publicado: (2005)

IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
por: Neuzillet, Yann, et al.
Publicado: (2017)

MRI for managing intermediate & low risk prostate cancer
por: Padhani, Anwar R
Publicado: (2014)

An Association of Human Papillomaviruses Low Risk and High Risk Subtypes with Skin Tag
por: Pezeshkpoor, Fakhrozaman, et al.
Publicado: (2012)

External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1
por: Almeida, Gilberto L., et al.
Publicado: (2016)

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
por: Bady, Pierre, et al.
Publicado: (2018)

An analysis of prognostic factors in a cohort of low-grade gliomas and degree of consistency between RTOG and EORTC scores
por: Pérez, Isaura Fernández, et al.
Publicado: (2022)

A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer
por: Neuzillet, Yann, et al.
Publicado: (2012)

Nitrogen Supply and Leaf Age Affect the Expression of TaGS1 or TaGS2 Driven by a Constitutive Promoter in Transgenic Tobacco
por: Wei, Yihao, et al.
Publicado: (2018)

Safety of early orthopedic surgery in patients with intermediate/low- or low-risk pulmonary embolism
por: Kim, Ho Cheol, et al.
Publicado: (2020)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Transcatheter Aortic Valve Replacement in Intermediate‐ and Low‐Risk Patients
por: Rogers, Toby, et al.
Publicado: (2018)

Laparoscopic surgery for low, intermediate and high-risk endometrial cancer
por: Vardar, Mehmet Ali, et al.
Publicado: (2018)

Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
por: Hartl, Dana M., et al.
Publicado: (2020)

Radioactive iodine in low- to intermediate-risk papillary thyroid cancer
por: Zhao, Hengqiang, et al.
Publicado: (2022)

Electron Cloud at Low Emittance in CesrTA
por: Palmer, Mark, et al.
Publicado: (2010)

Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
por: Jeong, Bae-Kwon, et al.
Publicado: (2015)

Active surveillance and focal therapy for low-intermediate risk prostate cancer
por: Klotz, Laurence
Publicado: (2015)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?
por: Katz, Alan J., et al.
Publicado: (2011)

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective
por: Koessler, T., et al.
Publicado: (2022)

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
por: Kishan, Amar U., et al.
Publicado: (2019)

No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
por: Cyll, Karolina, et al.
Publicado: (2022)

Screening with Magnetic Resonance Imaging in women at low and intermediate risk of breast Cancer
por: Huzarski, T T, et al.
Publicado: (2012)

Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer
por: Harder, Nathalie, et al.
Publicado: (2018)

The advantages of intermediate‐tier, inter‐optometric referral of low risk pigmented lesions
por: Ly, Angelica, et al.
Publicado: (2017)

Is the Calcium Score Useful for Rheumatoid Arthritis Patients at Low or Intermediate Cardiovascular Risk?
por: Jesson, Claire, et al.
Publicado: (2022)

Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution
por: Anderson, Elliot, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cstsv4l3c7f6ijbmb7m48uog0e